WHO Expert Committee on Drug Dependence. Thirty-second report.
This report presents the recommendations of a WHO Expert Committee responsible for reviewing information on dependence-producing drugs to assess the need for their international control. The first part of the report contains a general discussion of the new guidelines for the review of dependence-producing psychoactive substances and their implications for the scheduling of ephedrine and of the guidelines that were drafted to clarify the scope of control of stereoisomers. A summary follows of the Committee's evaluations of six substances (4-bromo-2,5-dimethoxyphenethylamine (2C-B), 4-methylthioamphetamine (4-MTA), gamma-hydroxybutyric acid (GHB), N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MDBD), diazepam and zolpidem), four of which (2C-B, 4-MTA, GHB and zolpidem) were recommended for international control. The report also discusses the substances that were pre-reviewed by the Committee, five of which (amfepramone, amineptine, buprenorphine, dronabinol and tramadol) were recommended for critical review at a future meeting.
D000662:Amphetamines / Q000009:adverse effects / Q000494:pharmacology; D002047:Buprenorphine / Q000009:adverse effects / Q000494:pharmacology; D002328:Carisoprodol / Q000009:adverse effects / Q000494:pharmacology; D003975:Diazepam / Q000009:adverse effects / Q000494:pharmacology; D003986:Dibenzocycloheptenes / Q000009:adverse effects / Q000494:pharmacology; D004053:Diethylpropion / Q000009:adverse effects / Q000494:pharmacology; D013759:Dronabinol / Q000009:adverse effects / Q000494:pharmacology; D004335:Drug and Narcotic Control; D017408:Guidelines as Topic; D006801:Humans; D006885:Hydroxybutyrates / Q000009:adverse effects / Q000494:pharmacology; D009294:Narcotics / Q000009:adverse effects* / Q000145:classification / Q000494:pharmacology; D010207:Papaver / Q000009:adverse effects; D010423:Pentazocine / Q000009:adverse effects / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000145:classification / Q000494:pharmacology; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology; D019966:Substance-Related Disorders / Q000209:etiology* / Q000517:prevention & control; D014147:Tramadol / Q000009:adverse effects / Q000494:pharmacology; D014944:World Health Organization; D000077334:Zolpidem
D000662:Amphetamines; D003986:Dibenzocycloheptenes; D006885:Hydroxybutyrates; D009294:Narcotics; D011619:Psychotropic Drugs; D011725:Pyridines; D002328:Carisoprodol; C011597:amineptin; C111420:4-hydroxybutyric acid; D014147:Tramadol; D002047:Buprenorphine; C078956:4-methylthioamphetamine; D013759:Dronabinol; D000077334:Zolpidem; D003975:Diazepam; D004053:Diethylpropion; D010423:Pentazocine